| Breathomics as Predictive Biomarker for Checkpoint Inhibitor Response (NCT04146064) | University Health Network, Toronto | 2020-02-24 |
| Suicide Plus Immune Gene Therapy for Advanced Melanoma (NCT03338777) | Hospital Italiano de Buenos Aires | 2020-02-20 |
| ENB003 Plus Pembrolizumab Phase 1b/2a in Solid Tumors (NCT04205227) | ENB Therapeutics, Inc | 2020-02-18 |
| Intensive Medicines Monitoring Study of Toripalimab Monoclonal Injection (Tuoyi) . (NCT04234620) | Shanghai Junshi Bioscience Co., Ltd. | 2020-02-15 |
| A Phase 1b Trial of ATRC-101 in Adults With Advanced Solid Malignancies (NCT04244552) | Atreca, Inc. | 2020-02-11 |
| IT-hu14.18-IL2 With Radiation, Nivolumab and Ipilimumab for Melanoma (NCT03958383) | University of Wisconsin, Madison | 2020-01-30 |
| Talimogene Laherparepvec With Pembrolizumab in Melanoma Following Progression on Prior Anti-PD-1 Based Therapy (MASTERKEY-115) (Mk-3475-A07/KEYNOTE-A07). (NCT04068181) | Amgen | 2020-01-22 |
| Symptom Management for YA Cancer Survivors (NCT04035447) | Duke University | 2020-01-22 |
| Effects of Acute and Chronic Exercise on Myeloid-Derived Suppressor Cells in Melanoma Patients (NCT05615883) | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | 2020-01-20 |
| LITT and Pembrolizumab in Recurrent Brain Metastasis (NCT04187872) | University of Florida | 2020-01-10 |
| Novel Mechanisms and Predictors of VEGF Receptor Inhibitor- or Immune Checkpoint Inhibitor-Associated Hypertension and Cardiovascular Disease (NCT03709771) | Vanderbilt University Medical Center | 2020-01-09 |
| A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of HH2710 in Patient With Advanced Tumors (NCT04198818) | Haihe Biopharma Co., Ltd. | 2020-01-07 |
| Adjuvant Treatment Determined By Pathological Response To Neoadjvuant Nivolumab (NCT04013854) | Abramson Cancer Center at Penn Medicine | 2020-01-01 |
| High-Risk Skin Cancers With Atezolizumab Plus NT-I7 (NCT03901573) | NeoImmuneTech | 2019-12-26 |
| Safety and Efficacy of AK104, a PD-1/CTLA-4 Bispecific Antibody, in Selected Advanced Solid Tumors (NCT04172454) | Akeso | 2019-12-20 |
| A Study of Treatment Patterns and Outcomes in Participants With Stage IIIA Melanoma Receiving Adjuvant Systemic Therapy (NCT05432622) | Bristol-Myers Squibb | 2019-12-19 |
| An Observational Study of Adjuvant (Post-surgery) Therapy With Nivolumab for Resected (Completely Removed) Melanoma in Australia (NCT04146324) | Bristol-Myers Squibb | 2019-12-12 |
| A Study of Modakafusp Alfa (TAK-573) Given by Itself and Together With Pembrolizumab in Adults With Advanced or Metastatic Solid Tumors (NCT04157517) | Teva Branded Pharmaceutical Products R&D LLC | 2019-12-12 |
| Impact of Therapeutic Patient Education on the Toxicity of Immune Checkpoint Inhibitors in Oncology (NCT03948724) | Institut Cancerologie de l'Ouest | 2019-12-11 |
| Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist) (NCT04198766) | Inhibrx Biosciences, Inc | 2019-12-10 |
| Atezolizumab in Combination With Bevacizumab in Patients With Unresectable Locally Advanced or Metastatic Mucosal Melanoma (NCT04091217) | Hoffmann-La Roche | 2019-11-25 |
| Focused Ultrasound Ablation and PD-1 Antibody Blockade in Advanced Solid Tumors (NCT04116320) | Craig L Slingluff, Jr | 2019-11-21 |
| Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors (NCT04157985) | Dan Zandberg | 2019-11-15 |
| Effectiveness Study of Nivolumab Compared to Placebo in Prevention of Recurrent Melanoma After Complete Resection of Stage IIB/C Melanoma (NCT04099251) | Bristol-Myers Squibb | 2019-10-28 |
| Safety and Efficacy of Sonocloud Device Combined With Nivolumab in Brain Metastases From Patients With Melanoma (NCT04021420) | Assistance Publique - Hôpitaux de Paris | 2019-10-24 |
| Targeted Radionuclide Therapy for Metastatic Melanoma [131I] ICF01012 (NCT03784625) | Centre Jean Perrin | 2019-10-18 |
| Study of NGM120 in Subjects With Advanced Solid Tumors, Pancreatic Cancer, and Prostate Cancer Using Combination Therapy (NCT04068896) | NGM Biopharmaceuticals, Inc | 2019-10-16 |
| Efficacy of metfOrmin in PrevenTIng Glucocorticoid-induced Diabetes in Patients With Brain Metastases (NCT04001725) | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | 2019-10-15 |
| Naptumomab Estafenatox in Combination With Durvalumab in Subjects With Selected Advanced or Metastatic Solid Tumor, Including a Cohort Expansion in Esophageal Cancer. (NCT03983954) | NeoTX Therapeutics Ltd. | 2019-10-10 |
| A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors (NCT04032704) | Seagen Inc. | 2019-10-09 |
| Safety and Efficacy of SB 11285 Alone and in Combination With Atezolizumab in Patients With Advanced Solid Tumors (NCT04096638) | invoX Pharma Limited | 2019-09-23 |
| GEN1042 Safety Trial and Anti-tumor Activity in Participants With Malignant Solid Tumors (NCT04083599) | Genmab | 2019-09-17 |
| Risk Information and Skin-cancer Education for Undergraduate Prevention (NCT03979872) | University of Utah | 2019-09-09 |
| PDR001 + Panobinostat for Melanoma and NSCLC (NCT03982134) | Muhammad Furqan | 2019-09-01 |
| ADP-A2M4CD8 as Monotherapy or in Combination With Either Nivolumab or Pembrolizumab in HLA-A2+ Subjects With MAGE-A4 Positive Tumors (SURPASS) (NCT04044859) | USWM CT, LLC | 2019-08-20 |
| ATL001 in Patients With Metastatic or Recurrent Melanoma (NCT03997474) | Achilles Therapeutics UK Limited | 2019-08-15 |
| A Retrospective Observational Study on the Long-term Effects of Ipilimumab-treated Pediatric Participants in the Dutch Melanoma Treatment Registry (DMTR) (NCT04196452) | Bristol-Myers Squibb | 2019-08-12 |
| An Efficacy Study of Adjuvant Treatment With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab in Participants With High-Risk Melanoma (KEYNOTE-942) (NCT03897881) | ModernaTX, Inc. | 2019-07-18 |
| High Dose IL-2 in Combination With Anti-PD-1 (NCT03991130) | Gregory Daniels | 2019-07-17 |
| The Combination of Anti-PD-1 With Radiotherapy in Previously Untreated Metastatic Melanoma (NCT04017897) | Yonsei University | 2019-07-03 |
| Study of Efficacy and Safety of BCD-217 (Anti-CTLA-4 and Anti-PD-1) Followed By BCD-100 (Anti-PD-1) Versus BCD-100 Monotherapy as First-Line Treatment in Patients With Unresectable or Metastatic Melanoma (NCT03913923) | Biocad | 2019-07-01 |
| ctDNA for Early Detection of Recurrence in Melanoma (NCT06246227) | Herlev and Gentofte Hospital | 2019-07-01 |
| BRAF-/MEK-Inhibition With Dabrafenib and Trametinib in Melanoma Patients (NCT03944356) | EuMelaReg gGmbH | 2019-07-01 |
| Validation of Molecular Diagnostic Assays to Detect Cancer Biomarkers in Blood and Primary Tumor in HNSCC/NSCLC/Melanoma (NCT04490564) | Pharmassist Ltd | 2019-06-25 |
| A Study to Compare Nivolumab Drug Product Process D to Nivolumab Drug Product Process C in Participants With Stage IIIa/b/c/d or Stage IV Melanoma After Complete Resection (NCT03980314) | Bristol-Myers Squibb | 2019-06-24 |
| A Safety, Pharmacokinetic and Clinical Activity Study of NUC-7738 in Patients With Advanced Solid Tumours and Lymphoma (NCT03829254) | NuCana plc | 2019-06-17 |
| Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid Tumors (NCT04234113) | SOTIO Biotech AG | 2019-06-13 |
| A Study to Evaluate Sotigalimab (APX005M) in Subjects With Unresectable or Metastatic Melanoma (NCT04337931) | Apexigen America, Inc. | 2019-06-12 |
| Evaluation of Sphingolipids as Predictive Biomarkers of Immune Checkpoint Inhibitor Response in Melanoma Patients (NCT03627026) | Institut Claudius Regaud | 2019-06-11 |
| Long-term, Non-interventional, Observational Study Following Treatment With Fate Therapeutics FT500 Cellular Immunotherapy (NCT04106167) | Fate Therapeutics | 2019-06-11 |
| A Phase II Study of the Interleukin-6 Receptor Inhibitor Tocilizumab in Combination With Ipilimumab and Nivolumab in Patients With Unresectable Stage III or Stage IV Melanoma (NCT03999749) | NYU Langone Health | 2019-06-11 |
| INCB039110 in Combination With Dabrafenib and Trametinib in Patients With BRAF-mutant Melanoma and Other Solid Tumors. (NCT03272464) | Massachusetts General Hospital | 2019-05-29 |
| A Study of XmAb®22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors (NCT03849469) | Xencor, Inc. | 2019-05-29 |
| Circulating Tumor DNA (ctDNA) for Early Treatment Response Assessment of Solid Tumors (NCT04354064) | Washington University School of Medicine | 2019-05-29 |
| Hydrochlorothiazide and Risk of Skin Cancer (NCT04334824) | Canadian Network for Observational Drug Effect Studies, CNODES | 2019-05-27 |
| Clinical Study to Evaluate OrienX010 in Combination With Toripalimab as Neoadjuvant Treatment in Advanced Melanoma (NCT04197882) | Peking University Cancer Hospital & Institute | 2019-05-27 |
| Study of CTX-471 as a Monotherapy or in Combination With Pembrolizumab in Patients Post PD-1/PD-L1 Inhibitors in Metastatic or Locally Advanced Malignancies (NCT03881488) | Compass Therapeutics | 2019-05-17 |
| War on Melanoma™ Public Health & Education Campaign (NCT04611568) | OHSU Knight Cancer Institute | 2019-05-14 |
| Study to Evaluate OrienX010 in Combination With JS001 in the Treatment of Stage IV (M1c) Liver Metastasis From Melanoma (NCT04206358) | Peking University Cancer Hospital & Institute | 2019-05-13 |
| Study of Safety and Efficacy of DKY709 Alone or in Combination With PDR001 in Patients With Advanced Solid Tumors. (NCT03891953) | Novartis Pharmaceuticals | 2019-05-07 |
| Neoadjuvant PD-1 Blockade in Patients with Stage IIB/C Melanoma (NCT03757689) | Abramson Cancer Center at Penn Medicine | 2019-05-06 |
| CAcTUS - Circulating Tumour DNA Guided Switch (NCT03808441) | The Christie NHS Foundation Trust | 2019-05-02 |
| A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors (NCT03872947) | Toray Industries, Inc | 2019-04-26 |
| Dietary Intervention in Patients with a History of Melanoma (NCT03950635) | M.D. Anderson Cancer Center | 2019-04-16 |
| MRx0518 in Patients With Solid Tumours Waiting Surgical Removal of the Tumour (NCT03934827) | Imperial College London | 2019-04-10 |
| BioForte Technology for in Silico Identification of Candidates for a New Microbiome-based Therapeutics and Diagnostics (NCT04136470) | Ardigen | 2019-04-01 |
| Evaluating the Effect of Nivolumab for Patients With In-transit Metastases Treated With Isolated Limb Perfusion (NCT03685890) | Vastra Gotaland Region | 2019-04-01 |
| Nivolumab, BMS-936558 in Combination with Relatlimab, BMS-986016 in Patients with Metastatic Melanoma Naïve to Prior Immunotherapy in the Metastatic Setting (NCT03743766) | John Kirkwood | 2019-03-29 |
| Fecal Microbial Transplantation in Combination With Immunotherapy in Melanoma Patients (MIMic) (NCT03772899) | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | 2019-03-27 |
| SL-279252 (PD1-Fc-OX40L) in Subjects With Advanced Solid Tumors or Lymphomas (NCT03894618) | Shattuck Labs, Inc. | 2019-03-26 |
| MEK Inhibitor FCN-159 To Treat Advanced Melanoma With NRAS-aberrant (Ia) and NRAS-mutant (Ib)or NF1-mutant(1b) (NCT03932253) | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. | 2019-03-21 |
| The PIONEER Initiative: Precision Insights On N-of-1 Ex Vivo Effectiveness Research Based on Individual Tumor Ownership (Precision Oncology) (NCT03896958) | SpeciCare | 2019-03-21 |
| PD-1 Antibody SHR-1210 Combined With Apatinib of First-line Treatment of Advanced Acral Melanoma (NCT03955354) | Peking University Cancer Hospital & Institute | 2019-03-05 |
| Ipilimumab and Nivolumab Followed by Adjuvant Nivolumab in Locally Advanced or Limited Metastatic Melanoma (NCT06566391) | European Institute of Oncology | 2019-03-05 |
| Analysis of Circulating Exosomes in Melanoma Patients (NCT05744076) | Centre Hospitalier Universitaire de Besancon | 2019-03-01 |
| The Use of Magtrace®/Sentimag® in Sentinel Node Biopsy for Malignant Melanoma. The Magmen Study. (NCT03898687) | Sahlgrenska University Hospital | 2019-03-01 |
| FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors (NCT03841110) | Fate Therapeutics | 2019-02-15 |
| Teaching Skin Self-Examination to First-degree Relatives of Melanoma Patients Using Mobile App Technology (NCT03177941) | Northwestern University | 2019-02-01 |
| Study to Evaluate the Safety of Pembrolizumab in Participants With Unresectable or Metastatic Melanoma or Non-small Cell Lung Cancer in India (MK-3475-593/KEYNOTE-593) (NCT03715205) | Merck Sharp & Dohme LLC | 2019-01-31 |
| Study of INBRX-105 and INBRX-105 With Pembrolizumab in Patients With Solid Tumors Including Head and Neck Cancer (NCT03809624) | Inhibrx Biosciences, Inc | 2019-01-30 |
| A Phase 1/2, Open-label, Multi-center Study of the Safety and Efficacy of Alomfilimab (KY1044) as Single Agent and in Combination With Anti-PD-L1 (Atezolizumab) in Adult Patients With Selected Advanced Malignancies (NCT03829501) | Kymab Limited | 2019-01-28 |
| ACCEPTABILITY AND WRITING FREQUENCY OF ADVANCED DIRECTIVES IN ONCO-DERMATOLOGY PATIENTS (NCT03822988) | Central Hospital, Nancy, France | 2019-01-21 |
| Live Biotherapeutic Product MRx0518 and Pembrolizumab Combination Study in Solid Tumors (NCT03637803) | 4D pharma plc | 2019-01-10 |
| Blood Sample Collection to Evaluate Biomarkers in Subjects With Untreated Melanoma (NCT03727087) | Exact Sciences Corporation | 2019-01-10 |
| A Study is to Understand the Treatment Patterns for Immunotherapy Agents and BRAF/MEK Inhibitors Used in the Treatment of Advanced Melanoma (NCT03696069) | Bristol-Myers Squibb | 2019-01-09 |
| Establishment and Standardization of a Platform for In-depth Tumour Profiling (TUPRO) in Patients With Melanoma (NCT06463509) | Reinhard Dummer | 2019-01-08 |
| Assessment of Current Biomarker Testing Practices for Common Solid Cancers in Precision Oncology in the Community Setting (NCT03804255) | ECOG-ACRIN Cancer Research Group | 2019-01-08 |
| Predictive Clinical Features for Response to Adjuvant Immunotherapy in Stage II,III and IV Resected Melanoma (NCT05527795) | Hospices Civils de Lyon | 2019-01-01 |
| Immune Related-adverse Events in Patients Receiving Immune Checkpoint Inhibitors (NCT04268368) | Università Politecnica delle Marche | 2019-01-01 |
| QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors (NCT03228667) | ImmunityBio, Inc. | 2018-12-11 |
| Predictive Value of Progastrin Titer at Diagnosis and of Progastrin Kinetics During Treatment in Cancer Patients (NCT03787056) | Hospices Civils de Lyon | 2018-12-04 |
| PVSRIPO for Patients With Unresectable Melanoma (NCT03712358) | Istari Oncology, Inc. | 2018-11-26 |
| OH2 Injection in Solid Tumors (NCT04386967) | Binhui Biopharmaceutical Co., Ltd. | 2018-11-22 |
| MGC018 With or Without MGA012 in Advanced Solid Tumors (NCT03729596) | MacroGenics | 2018-11-21 |
| Relative Bioavailability Study of Subcutaneous Injection Versus Intravenous Infusion of Pembrolizumab (MK-3475) in Participants With Advanced Melanoma (MK-3475-555/KEYNOTE-555) (NCT03665597) | Merck Sharp & Dohme LLC | 2018-11-19 |
| Serial Tumour Biopsies and Blood Biomarkers in Melanoma (NCT04493723) | The Christie NHS Foundation Trust | 2018-11-14 |
| Vaccination With 6MHP, With or Without Systemic CDX-1127, in Patients With Stage II-IV Melanoma (NCT03617328) | Craig L Slingluff, Jr | 2018-11-13 |
| Study of ADCT-301 in Patients With Selected Advanced Solid Tumors (NCT03621982) | ADC Therapeutics S.A. | 2018-11-09 |
| A Study of HX008 for the Treatment of Patients With Malignant Melanoma (NCT04749485) | Taizhou Hanzhong biomedical co. LTD | 2018-11-08 |
| Internet-based Intervention for Skin Self-Examination in Participants With Increased Risk for Melanoma (NCT03725449) | Rutgers, The State University of New Jersey | 2018-11-03 |